Role of Galanin Neuropeptide in Pathogenesis of Postural Disorders in Parkinson’s Disease

Abstract

INTRODUCTION: Postural disorders in Parkinson’s disease (PD) are symptoms with poorly understood pathogenesis, and the early objective diagnosis is difficult. In the literature, the influence of galanin neuromodulator on many structures of peripheral and central nervous system has been described, which indicates the probable involvement of the nervous system in the formation of motor disorders in PD.

AIM: To study the content of galanin neuromodulator in blood serum of patients with PD and to determine its effect on clinical manifestations of postural disorders.

MATERIALS AND METHODS: Seventy-three patients with PD diagnosis were examined, the control group included 22 healthy volunteers. The complaints, history and neurological status were evaluated. In the main group, ‘classic’ complaints and clinical manifestations were identified. The Hoehn and Yahr unified rating scale for PD was used. The content of galanin in blood serum was determined using the enzyme-linked immunoassay.

RESULTS: The stage of the disease on average was 2 [2; 3], severity of motor deficit on the unified PD assessment scale was 46 [36; 56] points. In 8 patients, severe postural disorders were identified, moderate disorders — in 21, mild disorders — in 28 patients, very mild — in 8 patients. The level of galanin in the main group was 6.0 [4.2; 10.3] pg/ml, which is considerably lower than in the control group (16.9 [9.8; 18.1] pg/ml; р = 0.001). The correlation analysis revealed the relationship between the level of galanin and severity of postural disorders (R = -0.73; p = 0.001). With the content of galanin above 26 pg/ml, no postural disorders were present in the patients, the content 8 pg/ml — 26 pg/ml was associated with the minimal and mild disorders, 5 pg/ml – 8 pg/ml — with moderate disorders, and the content below 5 pg/ml — with severe disorders.

CONCLUSION: Reduction of serum galanin level is associated with the degree of severity of postural disorders in Parkinson’s disease.

Keywords

Parkinson’s disease / motor disorders / postural disorders / camptocormia / galanin

References

[1] Chigaleychik LA, Karabanov AV, Poleshchuk VV, et al. Sovremennye tekhnologii izucheniya postural'nykh narusheniy pri bolezni Parkinsona. Bulletin of the Russian Military Medical Academy. 2018;20(3S):116–7. (In Russ).

[2] Чигалейчик Л.А., Карабанов А.В., Полещук В.В., и др. Современные технологии изучения постуральных нарушений при болезни Паркинсона // Вестник Российской военно-медицинской академии. 2018. Т. 20, № 3S (63). С. 116–117.

[3] Tiple D, Fabbrini G, Colosimo C, et al.Camptocormia in Parkinson disease: an epidemiological and clinical study. J Neurol Neurosurg Psychiatry. 2009;80(2):145–8. doi: 10.1136/jnnp.2008.150011

[4] Tiple D., Fabbrini G., Colosimo C., et al. Camptocormia in Parkinson disease: an epidemiological and clinical study // J. Neurol. Neurosurg. Psychiatry. 2009. Vol. 80, No. 2. P. 145–148. doi: 10.1136/jnnp.2008.150011

[5] Borodulina IV, Arestov SO, Gushcha AO. Clinical Features of Degenerative Spine Disease in Patients with Postural Disorders Associated with Parkinson’s Disease. Nervnyye Bolezni. 2019;(2):40–5. (In Russ).

[6] Бородулина И.В., Арестов С.О., Гуща А.О. Особенности дегенеративного поражения позвоночникау пациентов с постуральными нарушениями на фоне болезни Паркинсона // Нервные болезни. 2019. № 2. С. 40–45.

[7] Abe K, Uchida Y, Notani M. Camptocormia in Parkinson's disease. Parkinsons Dis. 2010;2010:267640. doi: 10.4061/2010/267640

[8] Abe K., Uchida Y., Notani M. Camptocormia in Parkinson's disease // Parkinsons Dis. 2010. Vol. 2010. P. 267640. doi: 10.4061/2010/267640

[9] Gamaleya AA, Fedorova NV, Tomskiy AA, et al. Camptocormia in Parkinson's disease: clinical and pathogenetic features. Annaly Klinicheskoy i Experimental’noy Nevrologii. 2012;6(4):10–7. (In Russ).

[10] Гамалея А.А., Федорова Н.В., Томский А.А., и др. Камптокормия при болезни Паркинсона: клинические и патогенетические аспекты // Анналы клинической и экспериментальной неврологии. 2012. Т. 6, № 4. С. 10–17.

[11] Somani A, Perry C, Patodia S, et al. Neuropeptide depletion in the amygdala in sudden unexpected death in epilepsy: A postmortem study. Epilepsia. 2020;61(2):310–8. doi: 10.1111/epi.16425

[12] Somani A., Perry C., Patodia S., et al. Neuropeptide depletion in the amygdala in sudden unexpected death in epilepsy: A postmortem study // Epilepsia. 2020. Vol. 61, No. 2. P. 310–318. doi: 10.1111/epi.16425

[13] Nakamura Y, Machida Y, Hanawa H, etal.Analysis of Relation- ships between Spinal Deformity and Walking Ability in Parkinson's Disease Patients. Spine Surg Relat Res. 2019;3(4):348–53. doi: 10.22603/ssrr.2018-0046

[14] Nakamura Y., Machida Y., Hanawa H., et al. Analysis of Relationships between Spinal Deformity and Walking Ability in Parkinson's Disease Patients // Spine Surg. Relat. Res. 2019. Vol. 3, No. 4. P. 348–353. doi: 10.22603/ssrr.2018-0046

[15] Upadhyaya CD, Starr PA, Mummaneni PV. Spinal deformity and Parkinson disease: a treatment algorithm. Neurosurg Focus. 2010;28(3):E5. doi: 10.3171/2010.1.FOCUS09288

[16] Upadhyaya C.D., Starr P.A., Mummaneni P.V. Spinal deformity and Parkinson disease: a treatment algorithm // Neurosurg. Focus. 2010. Vol. 28, No. 3. P. E5. doi: 10.3171/2010.1.FOCUS09288

[17] Wu Z, Autry AE, Bergan JF, et al. Galanin neurons in the medial preoptic area govern parental behavior. Nature. 2014;509(7500):325–30. doi: 10.1038/nature13307

[18] Wu Z., Autry A.E., Bergan J.F., et al. Galanin neurons in the medial preoptic area govern parental behavior // Nature. 2014. Vol. 509, No. 7500. P. 325–330. doi: 10.1038/nature13307

[19] Šípková J, Kramáriková I, Hynie S, et al. The galanin and galanin receptor subtypes, its regulatory role in the biological and pathological functions. Physiol Res. 2017;66(5):729–40. doi: 10.33549/physiolres.933576

[20] Šípková J., Kramáriková I., Hynie S., et al. The galanin and galanin receptor subtypes, its regulatory role in the biological and pathological functions // Physiol. Res. 2017. Vol. 66, No. 5. P. 729–740. doi: 10.33549/physiolres.933576

[21] Skorvanek M, Martinez–Martin P, Kovacs N, et al. Relation- ship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. Parkinsonism Relat Disord. 2018;52:83–9. doi: 10.1016/j.parkreldis.2018.03.027

[22] Skorvanek M., Martinez–Martin P., Kovacs N., et al. Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients // Parkinsonism Relat. Disord. 2018. Vol. 52. P. 83–89. doi: 10.1016/j.parkreldis.2018.03.027

[23] Orekhova OA, Fedorova NV, Gamaleia AA. Camptocormia in patients with Parkinson's disease. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2013;113(7–2):13–7. (In Russ).

[24] Орехова О.А., Федорова Н.В., Гамалея А.А. Камптокормия при болезни Паркинсона // Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2013. Т. 113, № 7–2. С. 13–17.

[25] George RJSt, Gurfinkel VS, Kraakevik J, et al. Case Studies in Neuro- science: A dissociation of balance and posture demonstrated by campto-cormia. J Neurophysiol. 2018;119(1):33–8. doi: 10.1152/jn.00582.2017

[26] George R.J.St., Gurfinkel V.S., Kraakevik J., et al. Case Studies in Neuroscience: A dissociation of balance and posture demonstrated by camptocormia // J. Neurophysiol. 2018. Vol. 119, No. 1. P. 33–38. doi: 10.1152/jn.00582.2017

[27] DeSèze MP, Creuzé A, de Sèze M, et al. An orthosis and physiotherapy programme for camptocormia: a prospective case study. J Rehabil Med. 2008;40(9):761–5. doi: 10.2340/16501977-0252

[28] DeSèze M.–P., Creuzé A., de Sèze M., et al. An orthosis and physio-therapy programme for camptocormia: a prospective case study // J. Rehabil. Med. 2008. Vol. 40, No. 9. P.761–765. doi: 10.2340/16501977-0252

RIGHTS & PERMISSIONS

Eco-Vector